Study of injectable ALK-N001 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new injectable drug called ALK-N001 in people with advanced solid tumors that have stopped responding to standard treatment. It's for various cancers including lung, breast, ovarian, cervical, pancreatic, liver, and esophageal cancer. The goal is to see if the drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have an advanced solid tumor that cannot be removed by surgery or has spread.
- Your cancer has progressed after at least one standard treatment, or no standard treatment is available.
- You have a measurable tumor (one that can be seen on scans) and are generally up and about (ECOG 0 or 1).
- Your major organs (bone marrow, liver, kidneys, heart, lungs) are working well enough, as shown by recent blood tests.
- You are not pregnant or breastfeeding, and agree to use birth control for 6 months after the last dose.
- You have not had certain prior treatments (e.g., DXD analogues, irinotecan) or active infections (like untreated hepatitis B/C or HIV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new drug called AK146D1 for people with advanced solid tumors that have not responded to standard treatments or no longer work. The goal is to see if it is safe and effective.
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
This trial tests an experimental injection called GKL-006 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and helps shrink or control the cancer.
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.